Eli Lilly Loses Appeal in Gemzar Patent Case - WSJ.com
Links shared publicly online about this topic.
- 988total visits
Eli Lilly Loses Appeal in Gemzar Patent Case - WSJ.com
A federal appeals court ruled Wednesday that an Eli Lilly Co. patent for anti-cancer drug Gemzar is invalid, a decision that may clear the way for generic competition to the drug late this year.
View full resource at online.wsj.com
Tags: Cancer Medication, Drug, Gemzar, Eli Lilly and Company
Most Recently Shared on July 29, 2010 at 12:45 am By:
WSJ: Eli Lilly Loses Appeal in Gemzar Patent Case. http://bit.ly/dgqvcy
Advertisement
